Kino Biosciences is described as changing how drugs may be discovered through the use of the firm's proprietary Vascularized Micro-Organ (VMO) platform. This system is the first to contain a 3D, perfused network of living dynamic human blood vessels. The company has also created organ-specific versions of these vessel networks. This is achieved by inserting tissues of interest -- such as cancers (the Vascularized Micro-Tumor - VMT) and normal brain with an intact blood-brain barrier (the Vascularized Micro-Brain - VMB). The perfused vessel network in these platforms has physiological flow and permeability, making them an ideal test platform to measure responses to stimuli such as shear or drugs.
